Skip to main content


Freshfields advises HUTCHMED (China) Limited on its HK$4.1bn triple primary listing and global offering on HKSE

Freshfields Bruckhaus Deringer (‘Freshfields’) has provided Hong Kong law advice to HUTCHMED (China) Limited (‘Hutchmed’) on the global offering and triple primary listing of 104 million of its shares (before any exercise of the Over-allotment Option) on the Hong Kong Stock Exchange (‘HKSE’). The transaction raised proceeds of approximately HK$4.1bn (before any exercise of the Over-allotment Option). Trading in the shares commenced today (30 June 2021).

Hutchmed is a global commercial-stage biopharmaceutical company focused on the discovery, development and commercialisation of targeted therapies and immunotherapies for the treatment of patients with cancer and immunological diseases. The company started operations in 2000 as a wholly owned subsidiary of CK Hutchison. Its shares have been traded on the AIM market of the London Stock Exchange since 2006, and its American Depositary Shares have been listed on Nasdaq since 2016.

The Freshfields team advising on the transaction was led by partner Grace Huang.

Notes to editors

About Freshfields Bruckhaus Deringer

Freshfields Bruckhaus Deringer LLP is a global law firm with a long track record of successfully advising the world's leading national and multinational corporations and financial institutions on ground-breaking and business-critical challenges. Our team of more than 2,800 lawyers and other legal professionals delivers global results from our 28 offices worldwide. Our commitment, local and multinational expertise and business know-how means our clients can rely on us when it matters most.